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Abstract
Agmatine, an endogenous polyamine and putative neuromodulator, is known to have neuroprotective effects on various neurons 
in the central nervous system. We determined whether or not topically administered agmatine could reduce ischemic retinal 
injury. Transient ocular ischemia was achieved by intraluminal occlusion of the middle cerebral artery of ddY mice (30-35 g) 
for 2 h, which is known to also induce occlusion of the ophthalmic artery. In the agmatine group (N = 6), a 1.0 mM agmatine-
containing ophthalmic solution was administered four times daily for 2 weeks before occlusion. In the control group (N = 6), a 
0.1% hyaluronic acid ophthalmic solution was instilled at the same times. At 22 h after reperfusion, the eyeballs were enucleated 
and the retinal sections were stained by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Transient ocular 
ischemia induced apoptosis of retinal cells in the entire retinal layer, and topically administered agmatine can significantly reduce 
this ischemic retinal injury. The proportion of apoptotic cells was definitely decreased (P < 0.001; Kruskal-Wallis test). Overall, 
we determined that topical agmatine application effectively decreases retinal damage in an in vivo ocular ischemic injury model. 
This implies that agmatine is a good candidate as a direct neuroprotective agent for eyes with ocular ischemic diseases.
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Agmatine is an endogenous aminoguanidine com-
pound formed by the decarboxylation of L-arginine, and 
has been reported to be a putative neuromodulator in 
neurons of the central nervous system (CNS) (1,2). Al-
though agmatine was initially described as a ligand for 
imidazoline receptors (3), it is now recognized to act as 
an agonist on imidazoline I and α2-adrenergic receptors, 
as an antagonist on N-methyl-D-aspartic acid (NMDA) 
receptors, and as an inhibitor of neuronal/inducible nitric 
oxide synthases (NOSs) (1,2).
A large body of experimental evidence has demon-
strated the neuroprotective effects of agmatine on various 
noxious neuronal injuries (4-6). Given the suggestions 
that agmatine can reduce neuronal loss after cerebral/
spinal cord ischemia (5,6), we confirmed its protective ef-
fects on hypoxia-induced apoptosis of RGC-5 cells in vitro 
(7). Although we also revealed that topically administered 
agmatine rescues retinal ganglion cells (RGCs) in the 
eyes of chronic ocular hypertensive rats (8), the in vivo 
data providing evidence for the neuroprotective effects of 
agmatine are not yet sufficient.
Theoretically, agmatine is a good neuroprotective 
drug candidate because of its high binding affinity for 
α2-adrenergic and NMDA receptors. Although various 
neuroprotective agents, including α2-adrenergic receptor 
agonists and NMDA receptor antagonists, have been widely 
studied, a novel candidate drug is not yet available (9). If 
we can prove the neuroprotective effects of agmatine and 
identify its mechanisms of action, agmatine might provide 
new therapeutic strategies as a neuroprotective drug.
In the present report, we determined whether or not 
topically administered agmatine could reduce retinal injury 
induced by transient ocular ischemia using intraluminal 
occlusion of the ophthalmic artery.
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Material and Methods
Animals and topical agmatine administration
A total of 12 adult male ddY mice (7 weeks old, 30 to 35 
g) were used for this study. The animals were maintained 
under controlled conditions with a 12:12-h light/dark cycle 
and standard food and water provided ad libitum. They 
were treated in accordance with the ARVO Statement for 
the Use of Animals in Ophthalmic and Vision Research 
after obtaining permission of the Institutional Animal Care 
and Use Committee. Every effort was made to minimize the 
number of animals sacrificed and their suffering throughout 
our experiments. 
An agmatine-containing ophthalmic solution (1.0 mM; 
Sigma-Aldrich, USA) was formulated as previously described 
(8). Mice in the agmatine group (N = 6) received agmatine 
eye drops in both eyes four times daily for 2 consecutive 
weeks. Mice in the control group (N = 6) received a 0.1% 
hyaluronic acid ophthalmic solution (Santen Pharmaceutical 
Co., Japan) in both eyes at the same times.
Transient ocular ischemia caused by ophthalmic 
artery occlusion
Intraluminal occlusion of the middle cerebral artery 
(MCA) was induced as previously described (10,11) using 
a silicone rubber-coated monofilament (Doccol Co., USA). 
Briefly, after the mice were anesthetized with an intraperi-
toneal injection of a mixture of zolazepam/tiletamine (80 
mg/kg; Zoletil 50®, Virbac, France) and xylazine (20 mg/
kg; Rompun®, Bayer HealthCare, Germany), the filament 
was introduced into the left internal carotid artery through 
an arteriotomy in the left common carotid artery. The fila-
ment was advanced up to the origin of the anterior cerebral 
artery and caused occlusion of the ophthalmic artery as 
well as the MCA (12).
After 2 h of occlusion, the animals were re-anesthetized 
and the filament was withdrawn to permit restoration of blood 
flow. After an additional 22 h, the mice were perfused with 4% 
paraformaldehyde and their eyeballs were enucleated.
Terminal deoxynucleotidyl transferase dUTP 
nick-end labeling (TUNEL)
The enucleated eyeballs were immersed overnight in 4% 
paraformaldehyde at 4°C and embedded in paraffin; 4-μm 
sections were cut parallel to the maximum circumference 
of the eyeball through the optic disc. Apoptotic cells were 
identified using TUNEL (DeadEnd™ Fluorometric TUNEL 
System; Promega, USA), and fluorescein isothyocyanate 
(FITC)-12-dUTP-labeled fragmented DNA was directly visu-
alized using a fluorescence microscope. Nuclear counter-
staining was performed using 4’,6-diamidino-2-phenylindole 
(DAPI). Four sections were selected from each eyeball and 
areas within a field between 375 and 625 µM from the optic 
disc were evaluated.
Results
Representative retinal sections of the TUNEL are shown 
in Figure 1. Mice in the control group were treated with 
a 0.1% hyaluronic acid ophthalmic solution (vehicle) in 
both eyes four times 
daily for 2 consecu-
tive weeks before 
occlusion of their left 
MCA. Their right eyes 
were defined as the 
‘no treatment control’ 
group (Figure 1A,B) 
and their left eyes 
were defined as the 
‘ocular ischemic injury 
only’ group (Figure 
1C,D). Mice in the 
agmatine group re-
ceived agmatine eye 
drops in both eyes 
four times daily for 2 
consecutive weeks 
before occlusion of 
their left ophthalmic 
artery. Their right eyes 
were defined as the 
‘agmatine treatment 
only’ group (Figure 
1E,F) and their left 
Figure 1. Representative retinal sections of terminal deoxynucleotidyl transferase dUTP nick-end labeling 
(TUNEL), in which the fluorescein isothyocyanate (FITC)-12-dUTP-labeled fragmented DNA and nuclear 
counterstaining were performed using 4’,6-diamidino-2-phenylindole (DAPI). A, B, No treatment control; C, 
D, ocular ischemic injury only; E, F, agmatine treatment only; G, H, ocular ischemic injury after agmatine 
treatment. A, C, E, G, Blue fluorescence indicates DAPI; B, D, F, H, green fluorescence indicates FITC. 
The TUNEL-positive cells are emphasized as yellow circles in Panels B, F, and H, but all cells are TUNEL-
positive in Panel D. Scale bar = 100 µM.
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eyes were defined as the ‘ocular ischemic injury after ag-
matine treatment’ group (Figure 1G,H).
In the retinas of the control group, a few TUNEL- positive 
apoptotic cells were noticed in the outer nuclear layer (Figure 
1B). Transient ocular ischemia definitely induced extensive 
retinal damage (Figure 1D); every single cell in the whole 
retinal layer was TUNEL-positive and large vacuolations 
were found in the inner nuclear and plexiform layers. How-
ever, topically administered agmatine dramatically reduced 
the proportion of apoptotic cells (P < 0.001; Kruskal-Wallis 
test) and improved the retinal integrity (Figure 1H).
Discussion
In this investigation, we demonstrated that topically 
administered agmatine effectively rescues retinal cells 
from ischemic damage. Although many researchers have 
used an acute ischemia-reperfusion injury model caused 
by a transient elevation in intraocular pressure (13-15), 
this animal model has the mixed pathophysiology of 
pressure-dependent and pressure-independent mecha-
nisms. Retrobulbar/intravitreal injection of endothelin-1 has 
also been reported to completely obstruct retinal vessels 
(16,17); however, this is a very expensive method and it 
is hard to control the duration of occlusion, especially in 
small rodents (18). Intraluminal MCA occlusion also causes 
transient/permanent occlusion of the ophthalmic artery (12). 
While intraluminal MCA occlusion requires a skilled techni-
cian, it can precisely control the time of occlusion. Thus, 
transient intraluminal occlusion of the MCA can serve as 
a useful experimental model that mimics ocular ischemia-
reperfusion injury.
Agmatine is a putative neuromodulator in CNS neurons 
(1,2) and is known to act as an agonist on imidazoline I 
and α2-adrenergic receptors, as an antagonist on NMDA 
receptors, and as an inhibitor of neuronal/inducible NOSs 
(1,2). Recently, agmatine has received considerable atten-
tion due to its neuroprotective effects on various neuronal 
injuries (4-6). Regarding ocular tissue, we demonstrated 
that agmatine protects damaged hypoxic RGC-5 cells (7) 
and that topically administered agmatine rescues RGCs 
in chronic ocular hypertensive rat eyes (8). In the present 
report, we investigated whether topically administered 
agmatine could reduce ischemic retinal injury. In a previ-
ous investigation, high concentrations of agmatine (0.1 M) 
were presumed to have caused corneal toxicity, while 1.0 
mM agmatine exhibited good ocular hypotensive effects 
(8). As such, in this study we also used 1.0 mM agmatine 
eye drops. In addition, since we have some evidence of the 
neuroprotective effects of agmatine pretreatment (19,20), 
we decided to start agmatine treatment before inducing 
ischemic injury.
Our results confirm that topically administered agmatine 
can significantly reduce ischemia-reperfusion retinal injury 
in a mouse model of transient ocular ischemia. Although the 
precise mechanisms of agmatine in this retinal protective 
process have not been well established, agmatine is a good 
potential candidate as a direct neuroprotective agent for 
eyes with ocular ischemic diseases, including glaucoma.
Acknowledgments
Research supported by a Faculty Research Grant from 
the Yonsei University College of Medicine, Seoul, Republic 
of Korea (#6-2010-0046).
References
 1. Reis DJ, Regunathan S. Is agmatine a novel neurotransmit-
ter in brain? Trends Pharmacol Sci 2000; 21: 187-193.
 2. Halaris A, Plietz J. Agmatine: metabolic pathway and spec-
trum of activity in brain. CNS Drugs 2007; 21: 885-900.
 3. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, 
Reis DJ. Agmatine: an endogenous clonidine-displacing 
substance in the brain. Science 1994; 263: 966-969.
 4. Gilad GM, Salame K, Rabey JM, Gilad VH. Agmatine treat-
ment is neuroprotective in rodent brain injury models. Life 
Sci 1996; 58: L-6.
 5. Gilad GM, Gilad VH. Accelerated functional recovery and 
neuroprotection by agmatine after spinal cord ischemia in 
rats. Neurosci Lett 2000; 296: 97-100.
 6. Kim JH, Yenari MA, Giffard RG, Cho SW, Park KA, Lee JE. 
Agmatine reduces infarct area in a mouse model of transient 
focal cerebral ischemia and protects cultured neurons from 
ischemia-like injury. Exp Neurol 2004; 189: 122-130.
 7. Hong S, Lee JE, Kim CY, Seong GJ. Agmatine protects 
retinal ganglion cells from hypoxia-induced apoptosis in 
transformed rat retinal ganglion cell line. BMC Neurosci 
2007; 8: 81.
 8. Hong S, Kim CY, Lee WS, Shim J, Yeom HY, Seong GJ. Ocu-
lar hypotensive effects of topically administered agmatine in 
a chronic ocular hypertensive rat model. Exp Eye Res 2010; 
90: 97-103.
 9. Cheung W, Guo L, Cordeiro MF. Neuroprotection in glau-
coma: drug-based approaches. Optom Vis Sci 2008; 85: 
406-416.
10. Hara H, Huang PL, Panahian N, Fishman MC, Moskowitz 
MA. Reduced brain edema and infarction volume in mice 
lacking the neuronal isoform of nitric oxide synthase after 
transient MCA occlusion. J Cereb Blood Flow Metab 1996; 
16: 605-611.
11. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Hara 
H. Proteomic approach with LCMS-IT-TOF identified an 
increase of Rab33B after transient focal cerebral ischemia 
in mice. Exp Transl Stroke Med 2010; 2: 20.
12. Steele EC Jr, Guo Q, Namura S. Filamentous middle cere-
bral artery occlusion causes ischemic damage to the retina 
in mice. Stroke 2008; 39: 2099-2104.
Topical agmatine on ischemic ocular injury 215
www.bjournal.com.br Braz J Med Biol Res 45(3) 2012
13. Ju WK, Lindsey JD, Angert M, Patel A, Weinreb RN. Gluta-
mate receptor activation triggers OPA1 release and induces 
apoptotic cell death in ischemic rat retina. Mol Vis 2008; 14: 
2629-2638.
14. Russo R, Cavaliere F, Berliocchi L, Nucci C, Gliozzi M, 
Mazzei C, et al. Modulation of pro-survival and death-
associated pathways under retinal ischemia/reperfusion: 
effects of NMDA receptor blockade. J Neurochem 2008; 107: 
1347-1357.
15. Sakamoto K, Ohki K, Saito M, Nakahara T, Ishii K. Histologi-
cal protection by donepezil against neurodegeneration in-
duced by ischemia-reperfusion in the rat retina. J Pharmacol 
Sci 2010; 112: 327-335.
16. Takei K, Sato T, Nonoyama T, Miyauchi T, Goto K, Hommura 
S. A new model of transient complete obstruction of retinal 
vessels induced by endothelin-1 injection into the posterior 
vitreous body in rabbits. Graefes Arch Clin Exp Ophthalmol 
1993; 231: 476-481.
17. Brooks DE, Kallberg ME, Cannon RL, Komaromy AM, Ol-
livier FJ, Malakhova OE, et al. Functional and structural 
analysis of the visual system in the rhesus monkey model of 
optic nerve head ischemia. Invest Ophthalmol Vis Sci 2004; 
45: 1830-1840.
18. Masuzawa K, Jesmin S, Maeda S, Kaji Y, Oshika T, Zaedi 
S, et al. A model of retinal ischemia-reperfusion injury in rats 
by subconjunctival injection of endothelin-1. Exp Biol Med 
2006; 231: 1085-1089.
19. Iizuka Y, Hong S, Kim CY, Kim SK, Seong GJ. Agmatine 
pretreatment protects retinal ganglion cells (RGC-5 cell line) 
from oxidative stress in vitro. Biocell 2008; 32: 245-250.
20. Iizuka Y, Hong S, Kim CY, Yang WI, Lee JE, Seong GJ. 
Protective mechanism of agmatine pretreatment on RGC-5 
cells injured by oxidative stress. Braz J Med Biol Res 2010; 
43: 356-358.
